Abstract 143P
Background
Cholangiocarcinoma (CCA) is the leading cause of death in patients (pts) with primary sclerosing cholangitis (PSC). PSC-related CCA is rare, and there has been no clinical analysis of survival outcomes following surgery, radiation therapy (RT), or systemic therapy. Risk of autoimmune disease flare with immunotherapy also has yet to be reported. We aim to characterize treatment responses and clinical outcomes in relation to tumor mutational profiles.
Methods
We conducted a retrospective analysis of clinical outcomes data and next-generation sequencing (NGS) data at MD Anderson Cancer Center in pts with PSC-related CCA. Patient characteristics were compared using Fisher’s exact test and Mann-Whitney U. Progression-free survival (PFS), recurrence-free survival (RFS), and overall survival (OS) were assessed using the log-rank test.
Results
30 patients available NGS data. The most frequent mutations were both KRAS and TP53 at 13 (43%) followed by CDKN2A at 4 (13%) then both SMAD4 and ARID1A at 3 (10%); 8 pts had KRAS and TP53 mutations. Those treated with localized therapy had statistically significant difference in OS compared to systemic therapy only (Table 143P). Patients who received RT, ablation, or Y90 had no G3/4 hepatic toxicity. No statistically significant differences were observed in PFS for systemic therapies (Table 143P). Median OS of those with KRAS or TP53 mutation was 13.8 months while that of those without KRAS or TP53 was 22.7 months (p=0.0034). Pts with TP53 or KRAS mutations trended toward worse PFS on 1st line systemic therapy but had no statistical difference. Nine (9) pts received immunotherapy. Four had concurrent autoimmune enteropathy; autoimmune disease flare did not occur. Table: 143P
Treatment outcomes
Treatment | Pts | Median RFS (months) | Pts | Median OS (months) | p-value |
Systemic therapy only | - | - | 17 | 14.6 | - |
Local vs Systemic | |||||
Surgery with adjuvant therapy | 10 | 16 | 3 | Not Reached | - |
RT/ablation/Y90 radioembolization | 10 | 8 | 8 | 19.2 | 0.0022 |
Any localized treatment | 20 | - | 11 | 22.7 | 0.0001 |
Systemic therapy | Median PFS | Median PFS | p-value | ||
All first-line therapy | 27 | 6.3 | |||
Gemcitabine-based vs Other | 17 | 5.9 | 10 | 6.3 | 0.6094 |
All second-line therapy | 9 | 4 | |||
5-fluorouracil-based vs Other | 3 | 4.1 | 6 | 6.3 | 0.2382 |
Conclusions
KRAS and TP53 mutations are the most common mutations and a poor prognostic marker in PSC-related CCA. No flare of autoimmune diseases occurred on immunotherapy. Selected patients who underwent local therapy outperformed those who did not.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
MD Anderson Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract